Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease
GLP-1 RAs appear to be well tolerated in patients with IBD, with observational evidence suggesting potential associations with improved weight, metabolic, and disease-related outcomes. Prospective, IBD-specific studies are required to confirm safety, clarify mechanisms, and define optimal patient selection.
Authors
- Maitreyi Raman (ORCID: https://orcid.org/0000-0002-9129-3632)
- Joëlle St‐Pierre (ORCID: https://orcid.org/0000-0002-7393-4950)
- Patrick Hamilton (ORCID: https://orcid.org/0000-0001-6703-3745)
- Brooke Maracle
- Deepan Hazra
- Stephanie Gold (ORCID: https://orcid.org/0000-0002-8451-6092)
- Diane Lorenzetti (ORCID: https://orcid.org/0000-0001-8423-3458)
- Steven Quan
- Asma Shaikh (ORCID: https://orcid.org/0000-0002-4396-4788)
Institutions
- University of Calgary (CA)
- South Health Campus (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-11-30
- DOI
- https://doi.org/10.1111/apt.70485
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59